Incorrect username and/or password, please try again or click to reset.

Class 4 Medicines Defect Information: Rifadin (rifampicin) 150mg Capsules (MDR 127-09/19)

2019-10-16 10:24:29 (1 month(s) ago)

Summary

Aventis Pharma Limited t/a Sanofi has informed the MHRA that a change to the Patient Information Leaflet concerning possible side effects for Rifadin (rifampicin) 150mg Capsules has not been implemented by the required …

Read full MHRA article

Respond to this alert